Navigation Links
MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy

ents to recover more quickly following short surgical and diagnostic procedures and could improve facility and physician practice efficiency."

Bronchoscopy Pivotal Trial Results

A randomized, double-blind, multi-center phase 3 study was conducted to determine the safety and efficacy of Aquavan for the sedation of patients undergoing flexible bronchoscopies. Patients enrolled in this trial had medical histories that included respiratory disorders (88%), vascular disorders (55%), metabolism and nutrition disorders (55%), and infections (52%). Of all patients enrolled in the trial, 62% were found to have a pulmonary or respiratory abnormality at screening including 52% with chronic obstructive pulmonary disease (COPD) and 20% with a lung mass.

A total of 252 patients were randomized and received either a control dose of 2.0 mg/kg Aquavan or a 6.5 mg/kg dose of Aquavan. Following administration of the initial bolus dose of the study drug, the design of this trial allowed a limited number of supplemental doses to be administered to maintain sedation during the procedure.

The primary endpoint of this trial was sedation success, defined as a patient having achieved three consecutive Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of less than or equal to 4 after administration of sedative medication and completion of the bronchoscopy procedure without the use of alternative sedative medication and without manual or mechanical ventilation. The secondary endpoint of treatment success was defined as completion of the procedure without the use of alternative sedative medication and without manual or mechanical ventilation. Additional endpoints included measures of patient satisfaction.

Among patients treated with an initial bolus dose of 6.5 mg/kg (n=150) of Aquavan, the sedation success rate was 88.7% compared to 27.5% of patients in the control arm (n=102) (p less than 0.001). The treatment success rate among patients t
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:9/22/2014)... , Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: ... site investigator at Emory University, presented long-term follow up ... neural stem cells in the treatment of amyotrophic lateral ... presentation, which occurred at the Annual Symposium on ALS ... , on Friday, and was not open to ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a global ... for medical and surgical procedures, among other core ... with Munich -based Brainlab to ... Navigation. This agreement applies to the US ... U.S. sales and all distribution outside the U.S. ...
(Date:9/22/2014)... 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... a phase I clinical trial in patients with ... tolerability, and immunogenicity of INO-3106. This immunotherapy targets ... aerodigestive cancers. Aerodigestive cancers affect the ... parts of the esophagus and windpipe. The unmet ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
(Date:9/22/2014)... a very familiar "lub-dub" pattern that speeds up or ... pattern itself isn,t as regular as you might think. ... vary even at a "constant" heart rateand that variability, ... Reduced heart rate variability (HRV) has been found to ... congestive heart failure and inflammation. For athletes, a drop ...
(Date:9/22/2014)... 22, 2014 WHO: LiveOps, Inc., ... customer service solutions. , WHAT: The 10th annual ... customer care for the connected consumer. Constant change ... offer new challenges and opportunities for customer experience ... identify best practices, network and learn from fellow ...
(Date:9/22/2014)... By Tara Haelle ... (HealthDay News) -- Measuring how quickly a child,s brain ... according to a new study. Observing children,s ... is currently possible, the study authors reported. "The ... information is associated with autism severity is hugely promising," ...
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... California for a three-day conference to discuss brain-related ... brain injury from concussions and neurodegenerative disorders. ... medical director affiliated with a Silverado memory care ... of dedicated expertise in memory care, hosts the ...
(Date:9/22/2014)... September 22, 2014 The report ... application, end user, and geography. The equipment segment ... physiotherapy equipment market, by product. However, the accessories ... CAGR in the forecast period, owing to the ... Electric stimulation and ultrasound segments are the fastest-growing ...
Breaking Medicine News(10 mins):Health News:Variability keeps the body in balance 2Health News:Variability keeps the body in balance 3Health News:Variability keeps the body in balance 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5
... offers a low cost, non-invasive alternative to conventional ... having coronary artery disease; true even if the ... a study performed at the Thomas Jefferson University ... patients who had one or more calcified coronary ...
... shown that babies exposed to tobacco in utero are ... are at increased risk for sudden infant death syndrome. ... these babies are also less likely to self-soothe and ... did not smoke during pregnancy. , Researchers from The ...
... the leading,provider of internet and digital information accessibility ... award-winning System Access,software. With this release, Serotek ... support for 64-bit operating systems. This is ... IT professionals,alike. , ...
... ROME, N.Y., Dec. 1 To help prevent the spread ... is using two new,products that kill germs on hands and ... According to Infection Prevention Director LeAnna Grace, the hospital,conducted a ... sanitizing lotion to evaluate how well they work and was ...
... is a statement from Jeff Levi, Ph.D., Executive Director of ... and Drug Administration,s (FDA) progress report on the Food Protection ... lacks a real plan for food protection. The staff ... some key initiatives to improve food safety, but they can ...
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" or ... significantly reduce costs, centralize core operations, and refocus the Company,s ... found significant market acceptance. The restructuring program includes: , ... personnel of eight full-time employees (40% of the workforce) , ...
Cached Medicine News:Health News:Newborns exposed to maternal smoking more irritable, difficult to soothe 2Health News:Serotek First to Offer 64-Bit Support 2Health News:MRSA and C. difficile Infections Reduced by 50% in Hospital Study 2Health News:MRSA and C. difficile Infections Reduced by 50% in Hospital Study 3Health News:TFAH Statement: FDA Food Protection Plan is Insufficient 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 3Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 4Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 5Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 6Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 7
... Western Blot Kits provide a sensitive and ... Borrelia burgdorferi. Proteins from the spirochete are ... antigens are fractionated according to molecular weight ... in the presence of sodium dodecyl sulfate. ...
Surgitie&trade Single Use Ligating Loops with Delivery System...
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO STITCH™ Single Use Loading Units....
Medicine Products: